Nilogen Oncosystems is a Tampa-based company that specializes in providing innovative and clinically-relevant 3D cancer models for translational immuno-oncology programs. Their patented tumoroid technology captures the full heterogeneity of individual tumors, including the intact tumor microenvironment (TME), allowing for a more accurate understanding of therapeutic response. With their comprehensive range of services, including tumor cell killing analysis, gene expression and proteomics analysis, high content imaging, flow cytometry, and multiplex cytokine assays, Nilogen Oncosystems delivers actionable insights to drive accurate decision-making in drug development programs.
By retaining the intact TME and capturing the full tumor heterogeneity, Nilogen Oncosystems' tumoroid technology reflects the clinical response rate seen in patients. Their immuno-oncology applications enable the elucidation of the mechanism of action, quantification of tumor cell killing, and evaluation of multiple drug combinations in the same patient tissue. With a focus on improving the treatment and quality of life for cancer patients, Nilogen Oncosystems is dedicated to helping companies develop oncology therapies of the future and improving their chances of success in clinical trials.
Generated from the website